Barriers to acceptance of the human papillomavirus prophylactic vaccine

Journal of Pediatric Infectious Diseases

Volumn 3, Issue 3, 2008, Pages 159-165

  Blumenthal, Jill ^a   Heyman, Katherine P ^a   Trocola, Robin M ^a   Slomovitz, Brian M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MORRISTOWN MEMORIAL HOSPITAL   (United States)

Author keywords

Acceptance; Barriers; HPV; Human papillomavirus vaccine; Sexually transmitted disease

Indexed keywords

PLACEBO; RECOMBINANT VACCINE; WART VIRUS VACCINE;

ANTIBODY TITER; ATTITUDE TO HEALTH; BRONCHOSPASM; CANCER RISK; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GYNECOLOGICAL EXAMINATION; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; MEDICAL CARE; MEDICAL EDUCATION; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; NAUSEA; OUTCOME ASSESSMENT; PAIN; PAPANICOLAOU TEST; PATIENT DECISION MAKING; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SWELLING; UNSAFE SEX; UTERINE CERVIX CANCER; VAGINA BLEEDING; VIRUS STRAIN; VIRUS TRANSMISSION; WART VIRUS;

EID: 52249089036     PISSN: 13057707     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0035-1556993     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention. Division of STD Prevention. HPV and HPV Prevention; Information for Health Care Providers. Revised August 2006. Available at http://www.cds.gov/std/HPV/ STDFact-HPV-vaccine-hcp.html. Accessed June 2, 2007.
2. E.F. Dunne, E.R. Unger, M. Sternberg et al., Prevalence of HPV infection among females in the United States, JAMA 297 (2007), 813-819.
3. D.D. Davey, M.H. Neal, D.C. Wilbur, T.J. Colgan, P.E. Styer and D.R. Mody, Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, Arch Pathol Lab Med 128 (2004), 1224-1229.
4. C. Lacey, C.M. Lowndes and K.V Shah, Burden and management of non-cancerous HPV-related conditions: BPV-6/11 disease, Vaccine 3 (2006), 35-41.
5. U.S. Food and Drug Administration. New vaccine prevents cervical cancer FDA Consumer Magazine, Sept-Oct 2006. Available at http://www.fda.gov/ fdac/features/2006/506_cirvical.html. Accessed May 20, 2007.
6. N. Muñoz, F.X. Bosch, S. de Sanjosé et al., Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med 348 (2003), 518-527.
7. C.E. Greer, C.M. Wheeler, M.B. Ladner et al., Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts, J Clin Microbiol 33 (1995), 2058-2063.
8. S. Inglis, A. Shaw and S. Koenig, Chapter 11: HPV vaccines: Commercial Research & Development, Vaccine 3 (2006), 99-105.
9. S.J. Goldie, D. Grima, M. Kohli, T.C. Wright, M. Weinstein and E. Franco, A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/ 18 vaccine, Int J Cancer 106 (2003), 896-904.
10. A.V Taira, C.P. Neukermans and G.D. Sanders, Evaluating human papillomavirus vaccination programs, Emerg Infect Dis 10 (2004), 1915-1923.
11. S.L. Kulasingam. and E.R. Myers, Potential health and economic impact of adding a human papillomavirus vaccine to screening programs, JAMA 290 (2003), 781-789.
12. D.M. Harper, Why am I scared of HPV? CA Cancer J Clin 54 (2004), 245-247.
13. National Survey of Family Growth, 2002. Available at http://www.cdc.gov/ nchs/nsfg. Accessed May 20, 2008.
14. Centers for Disease Control and, Prevention. Youth Risk Behavior Survey-Unitod States, 2005, MMWR 55(S S05) (2006), 1-112.
15. S.L. Rosenthal, Protecting their adolescents from harm: Parental views on STI vaccination, J Adolesc Health 37 (2005), 177-178.
16. L.A. Koutsky, K.A. Ault C.M. Wheeler et al., A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med 347 (2002), 1645-1651.
17. C. Mao, L.A. Koutsky, KA. Ault et al., Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstet Gynecol 107 (2006), 18-27.
18. L.L. Villa, R.L. Costa, C.A. Petta, et al., Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol 6 (2005), 271-278.
19. L.L. Villa, R.L. Costa, C. A. Petta et al., High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, Br J Cancer 95 (2006), 1459-1466.
20. L.A. Koutsky, K.A. Ault C.M. Wheeler et al., A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med 347 (2002), 1645-1651.
21. Food and Drug Administration. Product approval information-licensing action [package insert]. Gardasil (quadrivalent human papitlomavirus types 6,11, 16, 18). Merck & Co., Whitehouse Station, NJ. Available at http://www.fda.gov/cber/label/HPVmer060806LB.pdf.
22. L.E. Markowitz, E.F. Dunne, M. Saraiya et al., Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 56 (2007), 1-24.
23. L.L. Villa, K.A. Ault, A.R. Giuliano et al., Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18, Vaccine 24 (2006), 5571-5583.
24. S.L. Block, T. Nolan, C. Sattler et al., Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women, Pediatrics 118 (2006), 2135-2145.
25. National Conference of State Legislatures. HPV Vaccine Legislation 2007-2008. Available at http://www.ncsl.org/programs/health/ HPVvaccine.htm. Accessed July 15, 2008.
26. S. McCaffrey, States balk at Cancer Vaccine Mandate. Available at http://www.forbes.com/feeds/ap/2007/05/20/ap3739648.html Accessed May 20, 2007.
27. G.F. Sawaya and K. Smith-McCune, HPV vaccination-more answers, more questions, N Engl J Med 356 (2007), 1991-1993.
28. G.D. Zimet, R.M. Mays and J.D. Fortenberry, Vaccines against sexually transmitted infections: Promise and problems of the magic bullets for prevention and control, Sex Transm Dis 27 (2000), 49-52.
29. G.D. Zimet, S.M. Perkins, L.A. Sturm, R.M. Bair, B.E. Juliar and R.M. Mays, Predictors of STI vaccine acceptability among parents and their adolescent children, J Adolesc Health 37 (2005), 179-186.
30. E. Olshen, E.R. Woods, S.B. Austin, M. Luskin and H. Bauchner, Parental acceptance of the human papillomavirus vaccine, J Adolesc Health 37 (2005), 248-251.
31. J.A. Kahn, G.D. Zimet, D.I. Bernstein et al., Pediatricians' intention to administer human papillomavirus vaccine: The role of practice characteristics, knowledge, and attitudes, J Adolesc Health 37 (2005), 502-510.
32. J.M. Riedesel, S.L. Rosenthal, G.D. Zimet et al., Attitudes about human papillomavirus vaccine among family physicians, J Piadiatr Adolesc Gynecol 18 (2005), 391-398.
33. A.F. Dempsey and M.M. Davis, Overcoming barriers to adherence to HPV vaccination recommendations, Am J Manag Care 12 (2006), 484-491.
34. D.R. Blake, B.M. Weber and K.E. Fletcher, Adolescent and young adult women's misunderstanding of the term Pap smear, Arch Pediatr Adolesc Med 158 (2004), 966-970.
35. M. Pitts and T. Clarke, Human papillomavirus infections and risks of cervical cancer: What do women know? Health Educ Res 17 (2002), 706-714.
36. N.T. Brewer and K.I. Fazekas, Predictors of HPV vaccine acceptability: A theory-informed, systematic review, Prev Med 45 (2007), 107-114.
37. M.A. Gerend and Z.F. Magloire, Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults, J Adolesc Health 42 (2008), 237-242.
38. I.C. Scarinci, I.C. Garceces-Palacio and E.E. Partridge, An exanimation of acceptability of HPV vaccination among African American women and Latina immigrants, J Womens Health (Larchmt) 16 (2007), 1224-1233.
39. B. Holcomb, J.M. Bailey, K. Crawford and M.T. 4th Ruffin, Adults' knowledge and behaviors related to human papillomavirus infection, J Am Board Fam Pract 17, (2004), 26-31.
40. J..A Kahn, S.L. Rosenthal, T. Hamann and D.I. Bernstein, Attitudes about human papillomavirus vaccine in young women, Int J STD AIDS 14 (2003), 300-306.
41. A. McClelland and P. Liamputtong, Knowledge and acceptance of human papillomavirus infection, J Am Board Fam Pract 17 (2004), 26-31.
42. C.W Boehner, S.R. Howe, D.I. Bernstein and S.L. Rosenthal, Viral sexually transmitted disease vaccine acceptability among college students, Sex Transm Dis 30 (2003), 774-778.
43. R.M. Mays, L.A. Sturm and G.D. Zimet, Parental perspectives on vaccinating children against sexually transmitted infections, Soc Sci Med 58 (2004), 1405-1413.
44. E. Lazcano-Ponce, L. Rivera, E. Arillo-Santillán, I Salmerón, M. Hernández-Avila and N. Muñoz, Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico, Arch Med Res 32 (2001), 243-247.
45. B.M. Slomovitz, C.C. Sun, M. Frumovitz et al., Are women ready for the HPV vaccine? Gynecol Oncol 103 (2006), 151-154.
46. K. Davis, E.D. Dickman, D. Ferris and J.K. Dias, Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents, J Low Genit Tract Dis 8 (2004), 188-194.
47. J. Waller, L.A. Marlow and J. Wardle, Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: A qualitative study, Cancer Epidemiol Biomarkers Prev 15 (2006), 1257-1261.
48. N.T. Brewer, C.L. Cuite, J.E. Herrington and N.D. Weinstein, Risk compensation and vaccination: Can getting vaccinated cause people to engage in risky behaviors, Ann Behav Med 34 (2007), 95-99.
49. J.C. Abma, G.M. Martinez, W.D. Mosher and B.S. Dawson, Teenagers in the United States: Sexual activity, contraceptive use, and childbearing 2002, Vital Health Stat 23 (2004), 24: 1-48.
50. D. Kirby, The impact of schools and school programs upon adolescent sexual behavior, J Sex Res 39 (2002), 27-33.
51. G.D. Zimet, N. Liddon, S.L. Rosenthal, E. Lazcano-Ponce and B. Allen, Chapter 24: Psychosocial aspects of vaccine acceptability, Vaccine 24 (2006), 201-209.
52. L.A. Marlow, J. Waller and J. Wardle, Parental attitudes to pre-pubertal HPV vaccination, Vaccine 25 (2007), 1945-1952.
53. N.A. Constantine and P. Jerman, Acceptance of human papillomavirus vaccination among Californian parents of daughters: A representative statewide analysis, J Adoleic Health 40 (2007), 108-115.
54. J.C. Raley, K.A. Followwill, G.D. Zimet and K.A. Ault, Gynecologists' attitudes regarding human papilloma virus vaccination: A survey of Fellows of the American College of Obstetricians and Gynecologists, Infect Dis Obstet Gynecol 12 (2004), 127-133.
55. R.M. Mays and G.D. Zimet, Recommending STI vaccination to parents of adolescents: The attitudes of nurse practitioners, Sex Transm Dis 31 (2004), 428-432.
56. M.F. Daley, N. Liddon, L.A. Crane et al., A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination, Pediatrics 118 (2006), 2280-2289.
57. B. Duval, V. Gilca, S. McNeil et al., Vaccination against human papillomavirus: A baseline survey of Canadian clinicians' knowledge, attitudes and beliefs, Vaccine 25 (2007), 7841-7847.